Cart
sales@molnova.com
Semaxanib
CAS No. 194413-58-6
Semaxanib ( SU5416 )
Catalog No. M13045 CAS No. 194413-58-6
Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 102 | In Stock |
|
| 10MG | 178 | In Stock |
|
| 25MG | 314 | In Stock |
|
| 50MG | 538 | In Stock |
|
| 100MG | 659 | In Stock |
|
| 200MG | 897 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSemaxanib
-
NoteResearch use only, not for human use.
-
Brief DescriptionSemaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
-
DescriptionSemaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.
-
In Vitro——
-
In Vivo——
-
SynonymsSU5416
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR2/Flk1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number194413-58-6
-
Formula Weight238.28
-
Molecular FormulaC15H14N2O
-
Purity>98% (HPLC)
-
SolubilityEthanol: 2 mg/mL (8.39 mM); DMSO: 22 mg/mL (92.32 mM)
-
SMILESCC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fong TA, et al. Y Res, 1999, 59(1), 99-106.
molnova catalog
related products
-
Cabozantinib
Cabozantinib (XL184, BMS-907351) is a potent multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
-
Regorafenib
A potent multikinase inhibitor that potently inhibits these endothelial cell kinases in biochemical and cellular kinase phosphorylation assays with nanomolar range (IC50=3-200 nM).
-
8-O-Acetylshanzhisid...
8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppression of intracellular Ca2+ elevation and caspase-3 activity.
